Chemical Component Summary

FormulaC23 H28 F2 N6 O4 S
Molecular Weight522.57
Isomeric SMILESCCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1

Chemical Details

Formal Charge0
Atom Count64
Chiral Atom Count6
Chiral AtomsC12, C26, C29, C35, C38, C9
Bond Count68
Aromatic Bond Count16
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB08816 Different stereochemistry
DescriptionTicagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
  • (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • AZD 6140
  • AZD-6140
  • AZD6140
  • Brilinta
Brand Names
  • Brilinta
  • Brilique
  • Possia
Affected OrganismHumans and other mammals
IndicationFor the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation.
PharmacologyPlasma concentrations of ticagrelor are slightly increased (12–23%) in elderly patients, women, patients of Asian ethnicity, and patients with mild hepatic impairment. They are decreased in patients that described themselves as 'coloured' and such with severe renal impairment. These differences are considered clinically irrelevant. In Japanese people, concentrations are 40% higher than in Caucasians, or 20% after body weight correction. The drug has not been tested in patients with severe hepatic impairment.
Mechanism of actionLike the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. Moreover, the drug does not need hepatic activation, which might work better for patients with genetic variants regarding the enzyme CYP2C19 (although it is not certain whether clopidogrel is significantly influenced by such variants).
Route of administrationOral
  • Blood and Blood Forming Organs
  • Carbohydrates
  • Chemical Actions and Uses
  • Combined Inhibitors of CYP3A4 and P-glycoprotein
  • Cytochrome P-450 CYP2C9 Inhibitors
CAS number274693-27-5

Drug Targets

NameSequence SearchPharmacological ActionActions
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682